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Summary
Obesity is typically associated with elevated levels of free fatty acids (FFAs) and is linked to glucose intolerance and type
2 diabetes. FFAs exert divergent effects on insulin secretion from β cells: acute exposure to FFAs stimulates insulin secre-
tion, whereas chronic exposure impairs insulin secretion. The G protein-coupled receptor GPR40 is selectively expressed
in β cells and is activated by FFAs. We show here that GPR40 mediates both acute and chronic effects of FFAs on insulin
secretion and that GPR40 signaling is linked to impaired glucose homeostasis. GPR40-deficient β cells secrete less insulin
in response to FFAs, and loss of GPR40 protects mice from obesity-induced hyperinsulinemia, hepatic steatosis, hypertri-
glyceridemia, increased hepatic glucose output, hyperglycemia, and glucose intolerance. Conversely, overexpression of
GPR40 in β cells of mice leads to impaired β cell function, hypoinsulinemia, and diabetes. These results suggest that
GPR40 plays an important role in the chain of events linking obesity and type 2 diabetes.Introduction
Type 2 diabetes is strongly linked to visceral obesity and ele-
vated levels of circulating FFAs (Kahn and Flier, 2000; Zraika et
al., 2002; Yaney and Corkey, 2003; Kashyap et al., 2003; Moller
and Kaufman, 2005). The PPAR class of nuclear receptors bind
and respond to FFAs (Evans et al., 2004), and, recently, mem-
bers of the G protein-coupled class of transmembrane recep-
tors have been shown to be activated by FFAs (Briscoe et al.,
2003; Itoh et al., 2003; Kotarsky et al., 2003; Hirasawa et al.,
2005). Among these, GPR40 is preferentially expressed in pan-
creatic β cells (Briscoe et al., 2003; Itoh et al., 2003; Kotarsky
et al., 2003), and long-chain fatty acids enhance glucose-stim-
ulated insulin secretion (GSIS) from insulinoma cell lines in a
GPR40-dependent manner (Itoh et al., 2003). The effects of
FFAs on insulin secretion are, however, complex and divergent.
Acutely increased levels of FFAs enhance GSIS (Haber et al.,
2002; Zraika et al., 2002; Yaney and Corkey, 2003). In contrast,
prolonged exposure of β cells to high concentrations of FFAs
impairs several aspects of β cell function including GSIS (Ha-
ber et al., 2002; Zraika et al., 2002; Yaney and Corkey, 2003).
Typically, the development of type 2 diabetes is characterized
by an early state of hyperinsulinemia and glucose intolerance
that progresses to hypoinsulinemia and overt diabetes (Kahn,
1998; Taylor, 1999; Linghor et al., 2002). The dual and oppos-
ing effects of FFAs on insulin secretion raise the possibility that
FFAs contribute to both hyper- and hypoinsulinemia during the
development of type 2 diabetes.
The exact mechanism underlying the negative effects of
FFAs on β cell function and GSIS is not fully understood: the
majority of studies have been performed on clonal β cells or
isolated islets, and results have often been conflicting. Excess
FFAs have been proposed to affect GSIS via the Randle orCELL METABOLISM : APRIL 2005 · VOL. 1 · COPYRIGHT © 2005 ELSEVglucose/fatty acid oxidation cycle (Zhou and Grill, 1994; Zhou
and Grill, 1995; Zhou et al., 1996): other studies claim that in-
creased fatty acid oxidation does not impair glucose metabo-
lism in FFA-exposed β cells (Segall et al., 1999; Liu et al., 1999;
Boucher et al., 2004) and instead propose that FFAs perturb
the glucose-mediated increase in pyruvate cycling in β cells
(Iizuka et al., 2002; Boucher et al., 2004). In leptin signaling-
deficient animals with impaired fatty acid oxidation in β cells,
excess levels of circulating FFAs have been proposed to lead
to toxic accumulation of triglycerides in β cells (Shimabukuro
et al., 1998; Unger, 2002). FFAs stimulate PPARa activity and
expression in isolated islets and insulinoma cells, and adenovi-
ral-mediated expression of PPARa expression in isolated islets
or insulinoma cells stimulates fatty acid oxidation and impairs
GSIS (Zhou et al., 1998; Tordjman et al., 2002). Whether GPR40
contributes to the negative effects of FFA signaling on insulin
secretion from β cells, however, remains to be established.
Elevated levels of FFAs promote lipid accumulation and insu-
lin resistance in target tissues (Kahn and Flier, 2000; Haber et
al., 2002; Zraika et al., 2002; Yaney and Corkey, 2003; Kashyap
et al., 2003; Moller and Kaufman, 2005). Hyperinsulinemia and
elevated hepatic glucose output are hallmarks of insulin resis-
tance, and hyperinsulinemia per se has been proposed to con-
tribute to the development of insulin resistance, fatty liver/
hepatic steatosis, and increased hepatic glucose output (Kahn
and Flier, 2000; Wolfrum et al., 2004; Moller and Kaufman,
2005). Thus, under conditions of visceral obesity, FFA-stim-
ulated insulin secretion may promote hyperinsulinemia that
contributes to hepatic steatosis, increased hepatic glucose
output, and impaired glucose homeostasis. The role, if any, of
GPR40 in the development of obesity-induced hyperinsuli-
nemia and hepatic dysfunction remains, however, to be eluci-
dated.IER INC. DOI 10.1016/j.cmet.2005.03.007 245
A R T I C L EWe have used genetic approaches in mice to address the
role of GPR40 in insulin secretion and glucose homeostasis.
Our results provide evidence that GPR40 mediates both acute
and chronic effects of FFAs on insulin secretion in β cells. Loss
of GPR40 protects mice from obesity-induced hyperinsuli-
nemia, hepatic steatosis, hypertriglyceridemia, increased hepa-
tic glucose output, hyperglycemia, and glucose intolerance,
whereas transgenic overexpression of GPR40 in β cells leads
to impaired β cell function, hypoinsulinemia, and diabetes,
mimicking the overt diabetic state.
Results
Impaired insulin secretory response
to FFA in GPR40−/− mice
GPR40 is expressed in adult β cells of rodents with little or
no expression reported in peripheral tissues like liver, skeletal
muscle, or adipose tissue, and, although expression has been
reported in human brain, expression is not seen in brain of
mouse or rat (Briscoe et al., 2003; Itoh et al., 2003; Kotarsky
et al., 2003; see Figure S1 in the Supplemental Data available
with this article online). GPR40 expression was also observed
in insulin-positive cells of mice at embryonic day (E) 15 and 17
and in neonates (Figure 1A). Insulin-expressing cells are readily
detectable already at E13, but these cells do not express
GPR40 (data not shown), suggesting that GPR40 is expressed
preferentially in differentiated β cells. To investigate the role(s)
of GPR40 in vivo, we generated GPR40-deficient mice through
homologous recombination (Figures 1B–1D). The targeted
GPR40 allele contained lacZ-cDNA encoding the marker pro-
tein β-galactosidase (β-gal), thus allowing identification of tis-
sues in which the GPR40 promoter is active in heterozygous
and homozygous mutant mice. β-gal staining of tissues iso-
lated from GPR40+/− mice confirmed the preferential expres-
sion of GPR40 in pancreatic β cells, whereas no expression
could be detected in liver, fat, skeletal muscle, or brain (Figure
S2). GPR40−/− mice were viable, apparently healthy, lean, and
fertile. They showed no signs of diabetes, and fasting blood
glucose levels and glucose tolerance were normal (Figure 1E).
GPR40−/− mice displayed lower fasted serum insulin levels
than GPR40+/+ mice but maintained a biphasic insulin secre-
tory response upon glucose challenge (Figure 1F). Together,
these data provide evidence that, under normal nutritional con-
ditions, GPR40-mediated FFA signaling is not essential for in-
sulin secretion or maintenance of glucose homeostasis.
To test whether loss of GPR40 affects the β cell response to
FFAs, we examined whether islets from GPR40 null mice had
a perturbed insulin secretory response to FFAs. Palmitic acid
(PA) robustly stimulated insulin secretion from control islets but
not from islets isolated from GPR40−/− mice (Figures 2A and
2B), although these islets responded to increased glucose
levels (Figures 2A and 2B). These results confirm the proposed
role for GPR40 in mediating FFA stimulation of insulin secretion
(Itoh et al., 2003). To elucidate whether GPR40 also mediated
the long-term negative effect of FFAs on GSIS, we exposed
islets isolated from GPR40+/+ and GPR40−/− mice to PA for 48
hr. Long-term (48 hr) incubation of islets in the absence of FFAs
revealed a difference in insulin secretion from GPR40+/+ and
GPR40−/− islets that was not observed when performing short-
term (14 hr) incubation (Figures 2B and 2C). However, in vitro
culture of islets isolated from GPR40+/+ mice in the presence246of PA for 48 hr resulted, as expected, in attenuation of GSIS
compared to nonexposed islets (Figure 2C). In contrast, insulin
secretion from islets isolated from GPR40−/− mice was not im-
paired by 48 hr exposure to PA (Figure 2C), demonstrating that
GPR40−/− islets cultured in vitro are protected from the long-
term negative effect of FFAs on GSIS. Taken together, the com-
bined data derived from the short- and long-term exposure of
GPR40−/− and control islets to PA in vitro provide evidence that
GPR40 mediates both the short- and long-term effects of FFA
on GSIS.
GPR40−/− mice do not develop hyperinsulinemia
and glucose intolerance on HFD
To investigate how lack of GPR40 function affects insulin
secretion and glucose homeostasis in vivo under conditions of
obesity/increased FFA levels, we exposed GPR40+/+ and
GPR40−/− mice to a high-fat diet (HFD) for 8 weeks. HFD leads
to obesity and a variety of metabolic disturbances including
elevated FFA plasma levels, insulin resistance, hyperinsuli-
nemia, and glucose intolerance (Gregoire et al., 2002; Ross-
meisl et al., 2003; Wolfrum et al., 2004). GPR40−/− and
GPR40+/+ littermates gained weight similarly on the HFD and
became obese (Figures 3A and 3B). As expected, GPR40+/+
mice kept on HFD became hyperinsulinemic (Table 1 and Fig-
ures 3C and 3D); in contrast, fasted serum insulin levels and
glucose-stimulated insulin secretion were significantly lower in
GPR40−/− mice (Table 1; Figures 3C and 3D). GPR40+/+ mice
showed elevated fasted blood glucose levels and were glucose
intolerant (Table 1; Figures 3E and 3F), whereas GPR40−/− mice
did not develop significant glucose intolerance, and both non-
fasted and fasted blood glucose levels were lower than in con-
trol littermates (Table 1; Figures 3E and 3F and data not
shown). To begin to unravel the mechanism underlying the pro-
tection from diet-induced glucose intolerance in GPR40−/−
mice, we compared insulin sensitivity in these mice. No differ-
ence in insulin sensitivity was observed between GPR40+/+ and
GPR40−/− mice on control diet (CD) (Figure 3G). On HFD, both
GPR40+/+ and GPR40−/− mice developed insulin resistance but
GPR40−/− mice to a lesser extent (Figure 3H). Taken together,
these data show that, compared to GPR40+/+ littermates,
GPR40−/− mice kept on HFD secrete less insulin, do not de-
velop severe glucose intolerance, and become less insulin re-
sistant.
GPR40−/− mice are protected from hepatic steatosis
and hypertriglyceridemia
Mice kept on HFD develop fatty liver/hepatic steatosis and
hypertriglyceridemia and show elevated hepatic glucose out-
put (Gregoire et al., 2002; Rossmeisl et al., 2003; Wolfrum et
al., 2004). Hyperinsulinemia per se has been proposed to trig-
ger hepatic steatosis and hepatic insulin resistance (Kahn and
Flier, 2000; Wolfrum et al., 2004; Moller and Kaufman, 2005).
We therefore examined whether HFD-fed GPR40+/+ and
GPR40−/− mice developed hepatic steatosis and hypertriglyc-
eridemia. HFD treatment of GPR40+/+ mice led to a dramatic
increase in stored lipids in livers (Figure 4A). Serum triglyceride
levels were also increased in the HFD-fed GPR40+/+ mice (Ta-
ble 1). No similar increases were observed in HFD-treated
GPR40−/− mice (Figure 4A; Table 1). In several obese and dia-
betic animal models, hepatic steatosis is correlated with in-
creased hepatic glucose output that results from hepatic insu-CELL METABOLISM : APRIL 2005
GPR40 links FFA signaling to metabolic syndromeFigure 1. GPR40 expression and generation of GPR40−/− mice
A) GPR40 is expressed in fetal β cells. In situ hybridisation of E15, E17, and neonatal mouse pancreas using a DIG-labeled GPR40 cDNA probe, counterstained with
antibodies against insulin and/or glucagon as indicated.
B) Targeted disruption of the GPR40 gene. Structure of the wild-type and recombinant GPR40 locus; the localization of the probes (probe 1 and 2) used for genotyping
is indicated. X, XbaI; E, EcoRI.
C) Southern blot analysis of XbaI-digested genomic DNA from +/+, +/−, and −/− mice and the targeted ES cells clone (12D:3).
D) In situ hybridization of E16.5 wild-type and GPR40−/− pancreas for GPR40 mRNA. Scale bars, 20 m.
E) Glucose tolerance test in GPR40−/− ($; n = 12) and GPR40+/+ (■; n = 12) littermates. Blood glucose was measured at the indicated time points following intraperito-
neal (i.p.) injection of glucose.
F) Insulin secretion from pancreas of GPR40−/− (n = 7) and GPR40+/+ (n = 10) littermates during glucose tolerance test. Data represent the mean ± SEM.CELL METABOLISM : APRIL 2005 247
A R T I C L EFigure 2. FFA stimulation of insulin secretion in isolated islets
A−C) The effect on GSIS after short-term (2 hr; [A] and [B]) and long-term (48 hr; [C]) exposure to palmitic acid (0.5 mM) was measured using islets derived from
GPR40−/− (white bars; n = 4 in [A] and [B]; n = 3 in [C]) and wild-type (gray bars; n = 3 in [A] and [B]; n = 3 in [C]) littermates. Data represent the average values ± SEM.
***p < 0.001 for GPR40−/− versus GPR40+/+.lin resistance, and reversal of hepatic steatosis increases
hepatic insulin sensitivity (Matsusue et al., 2003; Wolfrum et
al., 2004). Thus, we next compared gluconeogenesis in HFD-
fed mice. In HFD-fed GPR40+/+ mice, administration of the glu-
coneogenic substrate pyruvate (Miyake et al., 2002) led to a
significant increase in blood glucose levels that persisted at
120 min (Figure 4C). However, pyruvate injection into HFD-fed
GPR40−/− mice resulted in a more modest increase in blood
glucose concentration that returned almost to basal levels by
120 min, similar to results obtained with CD-fed GPR40+/+ and
GPR40−/− mice (Figure 4B). Collectively, these data provide evi-
dence that GPR40−/− mice are protected from HFD-induced
hepatic steatosis, hypertriglyceridemia, and increased hepatic
glucose output.
To elucidate the mechanism underlying this differential
susceptibility to HFD-induced hepatic steatosis, we compared
the expression of genes that regulate lipid content, i.e., genes
involved in fatty acid synthesis, fatty acid oxidation, and fatty
acid uptake in GPR40+/+ and GPR40−/− mice kept on CD and
HFD. In agreement with previous observations (Kim et al.,
2004), the expression of genes involved in fatty acid synthesis
was either decreased (fatty acid synthase [FAS] and stearoyl-
CoA desaturase [SCD]) or unchanged (malic enzyme [MAL]) for
both groups of HFD-fed mice compared to mice on CD (Figure
4D). Accordingly, the expression of the transcription factor ste-
rol-regulatory element binding protein-1c (SREBP-1c) that
transcriptionally activates expression of lipogenic genes was248reduced in the HFD-fed mice compared to CD-fed mice (Figure
4D). The expression of CPT-1 was also unchanged in livers of
HFD-fed GPR40+/+ mice (Figure 4D), providing evidence that β
oxidation is not decreased in the HFD-fed GPR40+/+ mice.
PPARg expression is increased in livers of obese and diabetic
animal models (Chao et al., 2000; Memon et al., 2000; Be-
doucha et al., 2001; Rahimian et al., 2001) and has been di-
rectly linked to the development of fatty liver and hepatic insu-
lin resistance. Adenovirus-mediated overexpression of PPARg
in livers of mice leads to hepatic steatosis, and selective inacti-
vation of PPARg in livers of ob/ob and AZIP-F-1 mice reduces
hepatic steatosis (Gavrilova et al., 2003; Matsusue et al., 2003;
Yu et al., 2003). The expression of PPARg was upregulated in
livers of HFD-fed GPR40+/+ but not HFD-fed GPR40−/− mice
(Figure 4D). Consistent with this, expression of the PPARg
target gene fatty acid translocase (FAT/CD36) (Memon et al.,
2000; Yu et al., 2003) that stimulates fatty acid uptake by cells
(Schaffer, 2002) was also upregulated in livers of HFD-fed
GPR40+/+ mice (Figure 4D). Foxa2 activity in the liver has been
suggested to be regulated by insulin and to be inactive and
constitutively located to the cytoplasm in insulin-resistant and/
or hyperinsulinemic mice (Wolfrum et al., 2004). We did not
observe this phenomenon in our animals: we find Foxa2 pro-
tein in the nucleus of insulin-resistant, hyperinsulinemic, non-
fasted, HFD-fed mice (Figure S3). Collectively, these data sug-
gest that the hepatic steatosis observed in the HFD-fed control
mice is the consequence of increased fatty acid uptake ratherCELL METABOLISM : APRIL 2005
GPR40 links FFA signaling to metabolic syndromeFigure 3. Diet-induced obesity, hyperinsulinemia, and glucose intolerance
Weight increase (A and B), insulin secretion during glucose tolerance test (C and D), glucose tolerance (E and F), and insulin tolerance (G and H) were determined in
GPR40−/− ($) and GPR40+/+ (■) mice fed on control (CD) (A, C, E, and G) and high-fat diet (HFD) (B, D, F, and H) for 8 weeks.
A and B) Weight increase of GPR40−/− (CD, n = 6; HFD, n = 8) and GPR40+/+ (CD, n = 8; HFD, n = 13) mice was determined at 4 and 8 weeks of diet.
C and D) Serum insulin levels after i.p. injection of glucose in GPR40−/− (CD, n = 9; HFD, n = 9) and GPR40+/+ (CD, n = 6; HFD, n = 6) mice.
E and F) Blood glucose concentrations at the indicated time points following i.p. injection of glucose in GPR40−/− (CD, n = 6; HFD, n = 8) and GPR40+/+ (CD, n = 7;
HFD, n = 14) mice.
G and H) Blood glucose concentrations at the indicated time points following after i.p. injection of human insulin (0.75 units/kg body weight), in GPR40−/− (CD, n = 4;
HFD, n = 9), and GPR40+/+ (CD, n = 7; HFD, n = 9) mice. *p < 0.05 and **p < 0.01 for GPR40−/− versus GPR40+/+.CELL METABOLISM : APRIL 2005 249
A R T I C L ETable 1. Blood glucose, insulin, and triglyceride levels in fasted GPR40+/+ and GPR40−/− mice fed on a control or high-fat diet
Blood glucose (mmol/l) Insulin (g/l) Triglycerides (mmol/l)
GPR40+/+ (CD) n = 6 4.9 ± 0.3 0.2 ± 0.09 1.7 ± 0.1
GPR40+/+ (HFD) n = 12 9.6 ± 0.3 1.4 ± 0.25 3.2 ± 0.4
GPR40−/− (CD) n = 10 5.5 ± 0.4 0.2 ± 0.08 1.9 ± 0.3
GPR40−/− (HFD) n = 9 6.0 ± 0.6 0.5 ± 0.18 1.6 ± 0.3
p (wt versus GPR40−/− HFD) 0.03 0.01 0.0001
Blood glucose, triglycerides, and serum insulin levels were determined in overnight-fasted GPR40+/+ and GPR40−/− mice fed control (CD) or high-fat diet (HFD) for
8 weeks.than increased fatty acid synthesis or decreased fatty acid oxi-
dation. The results also provide evidence that GPR40, in an
indirect manner, is required for the HFD-induced expression of
PPARg and the target gene FAT/CD36 in liver cells and for the
development of hepatic steatosis and hypertriglyceridemia.
Transgenic overexpression of GPR40 in β cells
leads to diabetes
To try to mimic sustained GPR40 stimulation and the proposed
long-term negative effects of FFAs on insulin secretion (Haber
et al., 2002; Zraika et al., 2002; Yaney and Corkey, 2003), we
overexpressed GPR40 under the control of the Ipf1/Pdx1 pro-
moter (Apelqvist et al., 1997) in transgenic mice. Transgene
expression was confirmed both by in situ hybridisation and RT-
PCR (Figure S4 and data not shown). The Ipf1/GPR40 trans-
genic mice were born alive and lean and appeared initially heal-
thy but soon developed overt diabetes. The Ipf1/GPR40 mice
were glucose intolerant and exhibited a loss of first-phase insu-
lin release and a severely blunted second-phase insulin release
(Figures 5A and 5B). In contrast, mice overexpressing en-
hanced green fluorescent protein or the Cre-recombinase un-
der the control of the Ipf1/Pdx1 promoter did not show any
signs of hyperglycaemia or glucose intolerance when chal-
lenged with exogenous glucose (Figure S5). The diabetic
phenotype observed by overexpression of GPR40 in β cells
suggests that endogenous ligand(s) exists in excess or, alter-
natively, that the abundance of the receptor results in ligand-
independent receptor activation. The latter has been observed
for a number of different receptors, including G protein-cou-
pled receptors (Taylor et al., 1995; Wang et al., 1998; Malone
et al., 2004; Hoffmann et al., 2004). Thus, overexpression of
GPR40 in β cells, potentially mimicking chronic signaling, leads
to perturbed GSIS and diabetes, supporting the idea that sus-
tained stimulation of GPR40 is deleterious for β cell function
and insulin secretion.
To begin to unravel the mechanism by which overexpression
of GPR40 leads to perturbed β cell function and insulin secre-
tion, we examined the organization of the pancreas of 10-
week-old Ipf1/GPR40 and control mice. The pancreas from
Ipf1/GPR40 mice was morphologically normal (data not
shown), indicating that expression of GPR40 in the developing
pancreatic epithelium had no gross effect on pancreatic devel-
opment. Whole-mount immunostaining of the pancreas using
antibodies against insulin, glucagon, and smooth muscle
α-actin revealed an apparently normal organization of major
blood vessels and a normal amount, distribution, and size of
islets in the pancreas of the Ipf1/GPR40 transgenic mice (Fig-
ure 5C and data not shown). Moreover, immunohistochemical250analyses using antibodies directed toward activated cas-
pase-3 failed to detect an increase in apoptosis in the pancreas
of Ipf1/GPR40 mice (data not shown), providing evidence that
the impaired GSIS displayed by Ipf1/GPR40 mice is the result
of β cell dysfunction rather than β cell death. However, as ob-
served in other diabetic animal models (Hart et al., 2000; Yama-
gata et al., 2002), the postnatal organization of endocrine cells
within the islets was perturbed. In contrast to their normal pe-
ripheral localization, the glucagon-producing α cells were dis-
tributed throughout the islets (Figure 5C). Although the number
of β cells appeared normal in the Ipf1/GPR40 mice (data not
shown), the total pancreatic insulin content was reduced by
w50% (Figure 5D). Real-time (RT) PCR analyses of insulin
mRNA levels in islets derived from Ipf1/GPR40 and control
mice showed that insulin gene expression was normal in Ipf1/
GPR40 mice (Figure 5E), and, consistently, Ipf1/Pdx1 expres-
sion was reduced by at most w30% (Figure 6I). These results
suggest that the decrease in stored insulin in these mice may
be due to impaired biosynthesis of insulin protein and/or en-
hanced insulin secretion, resembling the situation observed in
islets after long-term exposure to high levels of FFAs (Bjorklund
and Grill, 1999; Furukawa et al., 1999).
Impaired expression of factors controlling glucose
sensing and proinsulin processing in Ipf1/GPR40 mice
To investigate whether the β cell dysfunction of Ipf1/GPR40
mice mimicked that of β cells exposed to FFAs also at the mo-
lecular level, we analyzed the expression of genes and proteins
that control aspects of β cell glucose metabolism and insulin
biosynthesis pathways and are affected by elevated levels of
FFAs. Long-term exposure of islets to elevated FFAs in vitro
results in impaired expression of glucose transporter 2 (Glut2)
(Gremlich et al., 1997), which, in mice, is required for normal β
cell function and glucose homeostasis (Guillam et al., 1997). In
the Ipf1/GPR40 mice, the expression of Glut2 mRNA and pro-
tein in islet cells was virtually undetectable (Figures 6A, 6E, and
6I). An increased proinsulin-to-insulin (P/I) ratio is observed in
many type 2 diabetics (Kahn et al., 1995; Nijpels et al., 1996;
Haffner et al., 1997; Larsson and Ahren, 1999), and long-term
exposure of islets to FFAs perturbs the biosynthesis and post-
translational processing of prohormone convertase 1/3 (PC1/3),
one of the key enzymes involved in proinsulin-to-insulin pro-
cessing, leading to impaired proinsulin processing (Bjorklund
and Grill, 1999; Furukawa et al., 1999). The level of PC1/3 pro-
tein but not mRNA appeared reduced in islet cells of Ipf1/
GPR40 mice (Figures 6B and 6F and data not shown); con-
versely, proinsulin immunoreactivity was significantly increased
in β cells of these mice (Figures 6C and 6G). The reduced ex-CELL METABOLISM : APRIL 2005
GPR40 links FFA signaling to metabolic syndromeFigure 4. Hepatic steatosis and increased glucose output in high-fat-diet-fed GPR40+/+ mice
A) Oil Red O staining of livers derived from GPR40+/+ and GPR40−/− mice after control diet (CD) and high-fat diet (HFD) treatment. Scale bar, 20 m.
B and C) Blood glucose concentrations at the indicated time points following i.p. injection of pyruvate (2 g/kg body weight) in GPR40−/− (CD, n = 3; HFD, n = 3) and
GPR40+/+ (CD, n = 6; HFD, n = 7) mice. *p < 0.05, **p < 0.01, and ***p < 0.001 for GPR40−/− versus GPR40+/+.
D) Quantitative real-time RT-PCR expression analyses of the indicated genes were performed using liver cDNA prepared from GPR40+/+ (CD, n = 5; HFD, n = 6) and
GPR40−/− (CD, n = 5; HFD, n = 7) mice on a control (CD) or high-fat diet (HFD). *p < 0.05 and **p < 0.01 for indicated animals on CD versus HFD.CELL METABOLISM : APRIL 2005 251
A R T I C L EFigure 5. Ipf1/GPR40 mice are glucose intolerant and have impaired glucose-stimulated insulin secretion
A) Blood glucose was measured in Ipf1/GPR40 ($, n = 7) and wild-type (■, n = 7) littermates at the indicated time points following i.p. injection of glucose.
B) Serum insulin levels during tolerance test in Ipf1/GPR40 (n = 7) and control littermates (n = 3). Data represent the mean value ± SEM. *p < 0.05; **p < 0.01; ***p <
0.001 for Ipf1/GPR40 versus wild-type littermates.
C) Whole-mount immunostained adult pancreas (upper panel) from wild-type and Ipf1/GPR40 mice showing blood vessels stained for smooth muscle α-actin (green)
and islets stained for insulin (pseudored) and glucagon (pseudoblue). Sectioned adult pancreas from wild-type and diabetic Ipf1/GPR40 mice stained for glucagon
(red) and insulin (green). Scale bar, 20 m.
D) Determination of total insulin content in isolated pancreas from diabetic Ipf1/GPR40 (gray bars) and wild-type controls (white bars); p = 0.09 for wild-type versus
Ipf1/GPR40.
E) Quantitative real-time RT-PCR of insulin mRNA from isolated islets of wild-type (white bars, n = 3) and Ipf1/GPR40 (gray bars, n = 3) mice.pression of Glut2 and PC1/3 and accumulation of unprocessed
proinsulin in β cells are likely to contribute to the development
and/or progression of diabetes in the Ipf1/GPR40 mice.
Altered expression of PPARα and target genes in islets
of Ipf1/GPR40 mice
PPARs act as intracellular receptors for FFAs; whereas PPARa
expression is upregulated in isolated islets and insulinoma cells252after exposure to FFAs (Zhou et al., 1998; Tordjman et al.,
2002), conflicting data exist regarding the effect of FFAs on
PPARγ expression in islets (Patanè et al., 2002; Lupi et al.,
2004). Although the role for PPARs in β cells is not fully under-
stood, in vitro studies suggest that PPARα stimulates fatty acid
oxidation and impairs insulin secretion (Zhou et al., 1998; Tordj-
man et al., 2002). Hence, we next investigated the expression
of PPARa and PPARg and genes whose expression has beenCELL METABOLISM : APRIL 2005
GPR40 links FFA signaling to metabolic syndromeFigure 6. Perturbed expression of genes involved in GSIS and insulin exocytosis in Ipf1/GPR40 mice
A–H) Sections of pancreas from wild-type (A–D) and diabetic Ipf1/GPR40 mice (E–H) stained for Glut2 (A and E), PC1/3 (B and F), proinsulin (C and G), and insulin (D
and H). Scale bar, 20 m.
I and J) Quantitative real-time RT-PCR expression analyses of the indicated genes were performed using islet cDNA prepared from Ipf1/GPR40 (gray bars, n = 3) and
wild-type (white bars, n = 3) mice. Data represent mean values ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001 for Ipf1/GPR40 versus wild-type littermates.linked, directly or indirectly, to PPAR expression and fatty acid
oxidation. We also analyzed the expression of genes involved
in β cell differentiation and function, lipogenesis, and cell
death. The expression of Isl1, glucokinase (GCK), hepatocyte
nuclear factor (HNF) 1- and 4a, Forkhead box (Fox) a2, sterol
regulatory element binding protein 1c (Srebp1c), carbohydrate
response element binding protein (Chrep), and bcl-2 genes
showed little or no change at the mRNA level (Figure 6I and
Figure S6). The expression of the nuclear FFA receptors PPARα
and PPARγ were, however, perturbed in islets of Ipf1/GPR40
mice; PPARa expression was upregulated w13-fold, whereas
the expression of PPARg was reduced by w35% (Figures 6I
and 6J) compared to that in control islets. The expression of
the FFA-inducible gene CPT1, which is a target gene forCELL METABOLISM : APRIL 2005PPARa (Assimacopoulos-Jeannet et al., 1997; Zhou et al.,
1998, Rubí et al., 2002; Tordjman et al., 2002) and encodes the
rate limiting enzyme in fatty acid oxidation, was upregulated
w6-fold in islets of Ipf1/GPR40 mice (Figure 6J). FFAs, fatty
acid oxidation, and direct overexpression of PPARa in an insu-
linoma cell line have also been shown to stimulate expression
of uncoupling protein 2 (UCP2), and UCP2 levels are inversely
correlated with GSIS both in vitro and in vivo (Lameloise et al.,
2001; Chan et al., 1999; Zhang et al., 2001; Chan et al., 2001;
Tordjman et al., 2002). UCP2 expression was increased by
w70% in islets of Ipf1/GPR40 mice (Figure 6I). It has been
proposed that a concomitant increase in both CPT1 and UCP2
contributes to the perturbation of GSIS in β cells after exposure
to FFA (Rubí et al., 2002). Thus, the increased expression of253
A R T I C L EPPARa and its target genes CPT1 and UCP2 in islets of Ipf1/
GPR40 mice are likely to contribute to the impaired GSIS and
development of diabetes observed in the Ipf1/GPR40 mice.
Discussion
Type 2 diabetes is strongly associated with obesity, and both
conditions are increasing at an alarming pace. Obesity is often
associated with elevated levels of FFAs, which promote lipid
accumulation in tissues, insulin resistance, hyperinsulinemia,
and hyperglycemia (Kahn, 1998; Taylor, 1999; Kahn and Flier,
2000; Kashyap et al., 2003; Moller and Kaufman, 2005). Overt
diabetes develops when β cells fail to compensate for the in-
creased demand for insulin, and sustained, elevated levels of
FFAs are believed to provoke not only insulin resistance but
also eventual β cell failure and hypoinsulinemia (Kahn, 1998;
Taylor, 1999; Kahn and Flier, 2000; Haber et al., 2002; Zraika et
al., 2002; Yaney and Corkey, 2003). Thus, obesity and elevated
levels of FFAs are linked to hyperinsulinemia, insulin resistance,
and glucose intolerance as well as to β cell failure, hypoinsuli-
nemia, and overt diabetes. Still, relatively little is known about
molecular mediators of FFA signaling in pancreatic β cells and
how these mediators contribute to the development of hyper-
and hypoinsulinemia during glucose intolerance and overt dia-
betes (Haber et al., 2002; Zraika et al., 2002; Yaney and Cor-
key, 2003). In the mouse, GPR40 is preferentially expressed in
β cells and activated by FFAs, and studies in cell lines have
suggested that FFAs stimulate insulin secretion from insu-
linoma cells through GPR40 (Briscoe et al., 2003; Itoh et al.,
2003; Kotarsky et al., 2003). Our results provide evidence that
GPR40 mediates both acute and long-term effects of FFAs on
insulin secretion in mouse and that GPR40 signaling is linked
to impaired glucose homeostasis.
Our data show that GPR40 function is not essential for glu-
cose homeostasis under normal nutritional conditions. How-
ever, GPR40−/− mice show reduced fasting insulin levels, and
isolated islets show a blunted insulin secretory response to
FFAs. These results are consistent with the idea that GPR40
mediates, at least in part, the stimulatory effect of FFAs on
insulin secretion. The finding that GPR40 is required for FFA-
stimulated insulin secretion raises the possibility that GPR40
contributes to obesity-induced hyperinsulinemia. In support of
this idea, our results provide evidence that, in contrast to
GPR40+/+ mice, GPR40−/− mice do not become hyperinsuli-
memic on a HFD. Moreover, under these conditions, GPR40−/−
mice do not develop hepatic steatosis, do not show an increase
in hepatic glucose output, and do not become hyperglycaemic.
These results support the idea that hyperinsulinema per se
contributes to hepatic steatosis, hepatic insulin resistance, and
hyperglycemia (Wolfrum et al., 2004; Moller and Kaufman,
2005). Gene expression analyses suggest that increased up-
take of FFAs by hepatocytes, and not increased FFA synthesis,
is a major cause of HFD-induced hepatic steatosis (Kim et al.,
2004). Consistent with these observations, we find that the ex-
pression of CD36, which mediates uptake of FFAs, is upregu-
lated in livers of GPR40+/+ but not GPR40−/− mice following
HFD treatment, whereas the expression of genes involved in
fatty acid synthesis is mainly unaffected. CD36 is a target gene
for PPARγ in liver cells (Memon et al., 2000; Yu et al., 2003),
and, accordingly, we find that PPARγ expression is also upreg-
ulated in fatty livers of GPR40+/+ mice compared to livers of254CD-fed mice and HFD-fed GPR40−/− mice. PPARγ is upregu-
lated in livers of several obese and diabetic animal models
(Chao et al., 2000; Memon et al., 2000; Bedoucha et al., 2001;
Rahimian et al., 2001), and PPARγ expression has been shown
to directly correlate to the development of hepatic steatosis
and hepatic insulin resistance; overexpression of PPARγ in liv-
ers of mice induces hepatic steatosis (Yu et al., 2003), whereas
selective inactivation of PPARγ in livers of two different mouse
models results in reduced hepatic steatosis (Gavrilova et al.,
2003; Matsusue et al., 2003).
Collectively, these results suggest that, under conditions of
elevated levels of FFAs, GPR40-mediated insulin secretion
leads to hyperinsulinemia, which in turn may contribute to the
development of hepatic steatosis and increased hepatic glu-
cose output and thereby to impaired glucose homeostasis. Ad-
ditional indirect effects of hyperinsulinemia on other targets tis-
sues cannot, however, be excluded and require further
investigation. Nevertheless, our results provide evidence that
loss of GPR40 protects mice from obesity-induced hyperinsuli-
nemia, hepatic steatosis, increased hepatic glucose output,
hyperglycemia, and glucose intolerance.
Chronically elevated levels of FFAs appear to have a nega-
tive effect on insulin secretion from β cells. Forced expression
of GPR40 in β cells leads to perturbed expression of genes
and proteins controlling glucose sensing, glucose metabolism,
proinsulin processing, and fatty acid oxidation and to the de-
velopment of diabetes, mimicking the long-term effects of
FFAs on β cell function and insulin secretion (Haber et al., 2002;
Zraika et al., 2002; Yaney and Corkey, 2003). Furthermore, cul-
tured GPR40−/− islets are protected from impairment of GSIS
caused by prolonged exposure to FFAs. Thus, our data sug-
gest that GPR40 is a mediator of the long-term, negative ef-
fects of FFAs on β cell function and GSIS. PPARs act as FFA
sensors and mediators of FFA signaling. Our observation that
forced expression of GPR40 in β cells leads to upregulation of
PPARa and downregulation of PPARg links GPR40 to intracel-
lular FFA signaling in β cells. Thus, GPR40 may mediate FFA
signaling in β cells both in a direct manner and also indirectly
by altering the expression of PPARs.
Although the roles of PPARs in β cell function remain poorly
understood, PPARa, as well as the target genes CPT1 and
UCP2, are linked to FFA-induced β cell dysfunction (Assimaco-
poulos-Jeannet et al., 1997; Rubí et al., 2002; Tordjman et al.,
2002; Patanè et al., 2002; Chan et al., 1999; Zhang et al., 2001;
Chan et al., 2001). FFAs stimulate the expression of these
genes in islets and insulinoma cell lines (Assimacopoulos-
Jeannet et al., 1997; Zhou et al., 1998; Lameloise et al., 2001;
Li et al., 2002; Tordjman et al., 2002), and adenovirus-mediated
increase of either CPT1 or UCP2 expression in vitro negatively
influences GSIS (Chan et al., 1999; Rubí et al., 2002; ). More-
over, both UCP2+/− and UCP2−/− mice show increased GSIS,
providing further evidence for the negative correlation between
UCP2 levels and insulin secretion (Zhang et al., 2001). UCP2
uncouples respiration from oxidative phosphorylation; hence,
increased UCP2 expression leads to reduced production of
ATP, an important stimulator of insulin secretion (Haber et al.,
2002; Zraika et al., 2002; Yaney and Corkey, 2003). Increased
CPT1 expression is known to stimulate fatty acid oxidation,
which has been proposed to inhibit GSIS by causing a decline
in pyruvate dehydrogenase activity (Zhou and Grill, 1994; Zhou
and Grill, 1995; Zhou et al., 1996) that in turn will attenuateCELL METABOLISM : APRIL 2005
GPR40 links FFA signaling to metabolic syndromeproduction of malonyl-CoA, a key metabolite in stimulation of
insulin secretion (Yaney and Corkey, 2003). The existence of a
glucose/fatty acid oxidation or Randle cycle in β cells is, how-
ever, a matter of controversy (Segall et al., 1999; Liu et al.,
1999; Boucher et al., 2004). We show that upregulation of
PPARα expression in islets of Ipf1/GPR40 mice is paralleled
by elevated levels of expression of CPT1 and UCP2, providing
evidence for a link between GPR40 and expression of PPARa,
CPT1, and UCP2. The combined increase in expression of both
CPT1 and UCP2 is likely to play a significant role in the severely
impaired GSIS displayed by Ipf1/GPR40 mice.
Ipf1/GPR40 mice also show altered expression of other
genes coupled to β cell function and insulin secretion. The ex-
pression of Glut2 mRNA and protein was severely reduced in
islets of Ipf1/GPR40 mice. Although not rate limiting, Glut2 ex-
pression is essential for efficient uptake of glucose into the β
cell, and Glut2 null mutant mice are glucose intolerant and lack
first-phase insulin secretion in response to glucose (Guillam et
al., 1997). Glut2 expression is also perturbed in several diabetic
animal models and in islets exposed to FFAs (Efrat, 1997;
Gremlich et al., 1997). Thus, the impaired expression of Glut2
in Ipf1/GPR40 mice may contribute to the impaired GSIS ob-
served in these mice. Exposure of islets to FFAs has little effect
on levels of PC1/3 mRNA but leads to impaired biosynthesis
of PC1/3 protein, leading to perturbed proinsulin processing
(Furukawa et al., 1999). Accordingly, mRNA levels of PC1/3
were not affected in β cells of Ipf1/GPR40 mice, but PC1/3
immunoreactivity was reduced, accompanied by accumulation
of proinsulin in the β cells.
Collectively, our data provide evidence that GPR40 mediates
both acute and chronic effects of fatty acids on β cells. Thus,
GPR40 may play a key role at multiple stages in the develop-
ment of type 2 diabetes. In the early phase, characterized by
obesity, hyperinsulinemia, and normoglycemia, elevated FFAs
lead to excessive stimulation of GPR40 signaling, resulting in
hyperinsulinemia, hepatic steatosis, and impaired glucose tol-
erance. These actions of GPR40 are revealed by the phenotype
of the GPR40−/− mice. In the later phase, chronic overstimula-
tion of GPR40 signaling eventually leads to impaired β cell
function, hypoinsulinemia, and overt diabetes, as seen in the
Ipf1/GPR40 transgenic mice. Since human GPR40 is also acti-
vated by FFAs and is expressed selectively (but not exclusively)
in β cells (Briscoe et al., 2003; Kotarsky et al., 2003), it seems
plausible that it plays a similar role as in mouse. Hence, GPR40
antagonists may represent a useful therapeutic strategy for the
prevention and treatment of obesity-associated type 2 dia-
betes.
Experimental procedures
Generation of transgenic and mutant GPR40 mice
A 930 bp XbaI-BglII GPR40 cDNA fragment was cloned behind the Ipf1
promoter and used for the generation of transgenic mice (Apelqvist et al.,
1997; Hogan et al., 1994). The primers used for genotyping were the follow-
ing: 5#-GGGAAGAGGAGATGTAGACTT-3# (Ipf1/Pdx1 primer) and 5#-GTA
GAGGGGAGCAAAGTG-3# (GPR40 primer). A targeting cassette including
IRES-nlslacZ (Arber et al., 1999), an SV40 polyadenylation signal, and a lox-
flanked pgk-neo cassette was used to replace the entire GPR40 coding
domain (Figure 1B; Hogan et al., 1994). A 493 bp 3# HinDIII–EcoRI fragment
was used to screen for ES cell recombinants (Figure 1B). GPR40−/− mice
were genotyped by PCR.CELL METABOLISM : APRIL 2005Oil Red O staining
Livers from four mice of each group were fixed in 4% PFA in 0.1 M PBS for
2 hr at 4°C, frozen, sectioned, stained with Oil Red O, and counterstained
with Meyer’s hematoxylin (DAKO).
Islet cultivation
Islets were isolated by collagenase digestion of pancreas (Ahren et al.,
1997), incubated 14 hr at 37°C in RPMI-1640 (GIBCO 21875-034 + 5.5 mM
glucose), and equilibrated in UB buffer (3.3 mM glucose) for 1 hr. Islets were
stimulated for 2 hr in UB buffer with low (3.3 mM) and high (20 mM) glu-
cose ± palmitic acid (final concentration, 0.5 mM; Sigma P9767-5G). For
long-term exposure of islets to FFAs, islets were incubated at 37°C in RPMI-
1640 (GIBCO 21875-034 + 5.5 mM glucose) ± palmitic acid (final concentra-
tion, 0.5 mM) for 48 hr prior to glucose stimulation. UB buffer (10×) was
prepared as follows: NaCl 14.6 g, KCl 880 mg, CaCl2 × H2O 376 mg,
MgCl2 × 6H2O 488 mg, and HEPES 11.9 g. Dissolve in 200 ml H2O. Upon
dilution, set pH 7.35 and add 0.1% BSA (ICN 105033, fatty acid free).
Mouse diet
Mice were fed ad libitum with a standard mouse chow (Lactamin, Stock-
holm, Sweden) and kept under a light-dark cycle of 12 hr. When stated,
8-week-old GPR40+/+ and GPR40−/− mice were put on a high-fat diet (58
kcal % fat) or control diet (10.5 kcal % fat) for 8 weeks (D12310 and
D12309, respectively, New Brunswick, NJ). Body weight and nonfasted
blood glucose levels (Glucometer Elite, Bayer Inc.) were monitored every
second week.
Glucose, insulin, and triglyceride measurements
Glucose tolerance and insulin secretion were measured in overnight-fasted
(12–16 hr) mice following intraperitoneal injection with 1 g/kg (dose/kg body
weight) glucose. Blood glucose levels were measured using a Glucometer
Elite (Bayer Inc.), triglycerides (TG) with Accutrend GCT (Roche), and serum
insulin levels were using ELISA (Mercodia). Total pancreatic insulin was ex-
tracted using acid ethanol (75% EtOH, 0.2 M HCl) and measured using a
Sensitive Rat Insulin RIA Kit (Linco). Total pancreatic protein concentration
was determined using Bio-Rad protein assay (Bio-Rad).
In situ hybridizations and immunohistochemistry
GPR40 in situ hybridizations and immunohistochemistry were carried out as
described elsewhere (Apelqvist et al. [1997] and www.mshri.on.ca/rossant/
protocols/DpERK%20Immunohistochem.html). At least 20 unique islets
were analyzed from three independent individuals from wild-type and Ipf1/
GPR40 mice for the immunohistology expression analyses. Primary anti-
bodies used were the following: guinea pig anti-insulin (Linco), mouse anti-
Pro-insulin (O.D. Madsen, Gentofte, Denmark), guinea pig anti-glucagon
(Linco), rabbit anti-glucagon (EuroDiagnostica), rabbit anti-glucose trans-
porter 2 (B. Thorens, Lausanne, Switzerland), rabbit anti-prohormone con-
vertase 1/3 (D. Steiner, Chicago), rabbit anti-cleaved caspase 3 (Cell Signal-
ing), rabbit anti-Foxa2 (T.M. Jessel, New York), FITC-conjugated mouse
anti-α-SMA (SIGMA), and rabbit anti-α-MSH (National Hormone and Pitu-
itary Program, NIDDK). Secondary antibodies used were the following:
ALEXA 488 anti-guinea pig, 594 anti-guinea pig (Molecular Probe), Cy3 anti-
rabbit, and Cy3-anti-rat (Jackson Laboratory).
Quantification of mRNA expression levels
cDNA was prepared from total RNA isolated from islets (Ahren et al., 1997)
and livers using NucleoSpin RNAII-kit (635990, Machery-Nagel) and Super
SMART PCR (635000, Clontech). RT-PCR analysis was performed using the
ABI PRISM 7000 Sequence Detection System and SYBR Green PCR Mas-
ter Mix (ABI) according to the manufacturers’ recommendations. Expression
of the 18S RNA (18S), β-2-microglobulin (b2M and TBP), was used to nor-
malize expression levels. Primer sequences were the following: 18S: 5#-
CACACGCTGAGCCAGTCAGT-3#, 5#-AGGTTTGTGATGCCCTTAGATGTC-3#;
b2M: 5#-GCTATCCAGAAAACCCCTCAAA-3#, 5#-CTGTGTTACGTAGCAGT
TCAGTATGTTC-3#; Bcl2: 5#-ACCGGCATCTGCACACCT-3#, 5#-CACAAAG
GCATCCCAGCC-3#; TBP: 5#-GAATTGTACCGCAGCTTCAAAA-3#, 5#-AGT
GCAATGGTCTTTAGGTCAAGTT; GCK: 5#-GCTTTTGAGACCCGTTTTGTG-
3#, 5#-GAGTGCTCAGGATGTTAAGGATCTG-3#; Glut2: 5#-TCCTCGTGG
CGCTGATG-3#, 5#-CTGGTTGAATAGTAAAATATCCCATTGAT-3#; Ipf1/Pdx1:
5#-TAGGACTCTTTCCTGGGACCAA-3#, 5#-AATAAAAAGGGTACAAACTTG255
A R T I C L EAGCGT-3#; Isl1: 5#-ATTGCCGCAACCAACACA-3#, 5#-CATGGGCGATCCA
CCAAA-3#; Ins: 5#-CCACCCAGGCTTTTGTCAA-3#, 5#-TCCCCACACACC
AGGTAGAGA; PC1/3: 5#-TGGAGGCAAACCCAAATCTTAC-3#, 5#-GAG
TACGACCCATTGGCCAG-3#; PPARa: 5#-GACAAGGCCTCAGGGTACCA-
3#, 5#-GCCGAATAGTTCGCCGAAA-3#; PPARg: 5#-AAGGCGAGGGCGAT
CTTG-3#, 5#-ATCATTAAGGAATTCATGTCGTAGATGAC-3#; UCP2: 5#-CAG
GTCACTGTGCCCTTACCA-3#, 5#-AGGCATGAACCCCTTGTAGAAG-3#;
CPT1: 5#-GGCTCATTTCCGGGAACAAA-3#, 5#-GGTACAGGAACGCACA
GTCTCA-3#; SREBP1: 5#-TGCGTGGTTTCCAACATGAC-3#, 5#-TGGCCT
CATGTAGGAATACCCT-3#; FAS: 5#-GGAGTTCTCAGGCCGGGATA-3#, 5#-
GGGTACATCCCAGAGGAAGTCA-3#; SCD: 5#-GGCCTGTACGGGATCATA
CTG-3#, 5#-GGTCATGTAGTAGAAAATCCCGAAGA-3#; MAL: 5#-GCTGGC
TAATATTCAGGAAGTTTCTG-3#, 5#-GGGTACCGGAAGGCCATTT-3#; FAT/
CD36: 5#-TCATATTGTGCTTGCAAATCCAA-3#, 5#-GCTTTACCAAAGATGT
AGCCAGTGT-3#; HNF1α: 5#-CAGCACCAGTCCCACAGTGT-3#, 5#-GGCT
GTGCCCGTTGGA-3#; HNF4α: 5#-ACGTGCTGCTCCTAGGCAAT-3#, 5#-GAT
GGACACACGGCTCATCTC-3#; Foxa2: 5#-GAGCCATCCGACTGGAGCA-3#,
5#-GGAATGAGCCCGTCGCTAG-3#; GPR40: 5#-TTTCATAAACCCGGACC
TAGGA-3#, 5#-CCAGTGACCAGTGGGTTGAGT-3#; Chrebp: 5#-ACTCAGG
GAATACACGCCTACAG-3#, 5#-TCTTGGTCTTAGGGTCTTCAGGAA-3#.
Supplemental data
Supplemental Data include six figures and Supplemental Experimental
Procedures and can be found with this article online at http://www.
cellmetabolism.org/cgi/content/full/1/4/245/DC1.
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